» Articles » PMID: 6754120

Efficacy of Various Durations of Isoniazid Preventive Therapy for Tuberculosis: Five Years of Follow-up in the IUAT Trial. International Union Against Tuberculosis Committee on Prophylaxis

Overview
Specialty Public Health
Date 1982 Jan 1
PMID 6754120
Citations 172
Affiliations
Soon will be listed here.
Abstract

A total of 28 000 persons with fibrotic pulmonary lesions compatible with tuberculosis were followed for five years after receiving 12, 24, or 52 weeks of preventive treatment with isoniazid or placebo.Compared with placebo, 12 weeks of isoniazid eliminated less than one-third, and 24 weeks eliminated two-thirds of the tuberculosis risk. Where preventive treatment is not currently practised, adopting a 24-week regimen could decrease the incidence of tuberculosis in such populations by 65%.Hepatitis, the only serious side-effect encountered, occurred infrequently but was more common among isoniazid recipients (0.5%) than among placebo recipients (0.1%).Fifty-two weeks of isoniazid prevented the most tuberculosis, but 24 weeks prevented more tuberculosis cases per case of hepatitis caused. Where preventive treatment is currently practised for 52 weeks, adopting a 24-week regimen would decrease hepatitis by one-third and increase tuberculosis by 40%.

Citing Articles

Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States.

Shrestha S, Cilloni L, Beeler Asay G, Kammerer J, Raz K, Shaw T Emerg Infect Dis. 2025; 31(3):497-506.

PMID: 40023804 PMC: 11878319. DOI: 10.3201/eid3103.240633.


Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.

Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori G, Goletti D Front Immunol. 2025; 16:1494283.

PMID: 39963138 PMC: 11830708. DOI: 10.3389/fimmu.2025.1494283.


Clinical perspectives of isoniazid-induced liver injury.

Lei S, Gu R, Ma X Liver Res. 2025; 5(2):45-52.

PMID: 39959342 PMC: 11791842. DOI: 10.1016/j.livres.2021.02.001.


The Management of Hematopoietic Stem Cell Transplant in People with HIV.

Dickter J, Moc Willeford C Viruses. 2024; 16(10).

PMID: 39459894 PMC: 11512245. DOI: 10.3390/v16101560.


Diagnosis and Treatment of Latent Tuberculosis Infection in Adults in South Korea.

Jo K, Yoon Y, Kim H, Kim J, Kang Y Tuberc Respir Dis (Seoul). 2024; 88(1):56-68.

PMID: 39374926 PMC: 11704725. DOI: 10.4046/trd.2024.0122.


References
1.
BUSH Jr O, Sugimoto M, Fujii Y, BROWN Jr F . Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report. Am Rev Respir Dis. 1965; 92(5):732-40. DOI: 10.1164/arrd.1965.92.5.732. View

2.
EGSMOSE T, ANGAWA J, Poti S . The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ. 1965; 33(3):419-33. PMC: 2475854. View

3.
Comstock G, FEREBEE S, HAMMES L . A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967; 95(6):935-43. DOI: 10.1164/arrd.1967.95.6.935. View

4.
Woolpert S, Dankova D, Krebs A, Vadasz I . [UICT survey on the length of preventive treatment of subjects with fibrous lesions--1st results. General Introduction]. Bull Int Union Tuberc. 1974; 49(1):302-5. View

5.
Krebs A . The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions. Bull Int Union Tuberc. 1976; 51(1):193-201. View